Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3
Summary. Albinterferon alfa-2b (albIFN) is a fusion protein of recombinant human albumin/recombinant interferon (IFN)-α-2b, with ∼200-h half-life. Safety/efficacy of albIFN q4wk was evaluated in 391 treatment-naive patients with chronic hepatitis C virus (HCV) genotype 2/3. Patients were randomized...
Saved in:
Main Authors: | Pianko S., Zeuzem S., Chuang WL., Foster GR., Sarin SK., Flisiak R., Lee CM., Andreone P., Piratvisuth T., Shah S., Sood A., George J., Gould M., Komolmit P., Thongsawat S., Tanwandee T., Rasenack J., Li Y., Pang M., Yin Y., Feutren G., Jacobson IM., for the B2202 Study Team. |
---|---|
格式: | Article |
語言: | English |
出版: |
2014
|
在線閱讀: | http://www.ncbi.nlm.nih.gov/pubmed/22863266 http://cmuir.cmu.ac.th/handle/6653943832/4001 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
機構: | Chiang Mai University |
語言: | English |
相似書籍
-
Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3
由: Pianko S., et al.
出版: (2014) -
Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3
由: S. Pianko, et al.
出版: (2018) -
Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin
由: G. R. Foster, et al.
出版: (2018) -
Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin
由: G. R. Foster, et al.
出版: (2018) -
Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis B infection
由: Colvin,R.A., et al.
出版: (2015)